Wenbin Jiang, CEO and Co-Founder of Cytek Biosciences, Inc.
Precision medicine is changing healthcare in ways that will touch nearly everyone’s life. Whether it is waiting for answers after an unexpected diagnosis, watching a loved one navigate cancer treatment, caring for aging parents or simply expecting more personalized experiences in every aspect of life, people increasingly expect healthcare to deliver treatments tailored to the individual, not the average patient.
For leaders across healthcare and life sciences, this shift represents a fundamental change in how organizations approach research, diagnosis, treatment and patient outcomes.
Precision medicine uses an individual’s biological characteristics (including genetics, proteins and cellular biomarkers) to understand disease, guide treatment and improve outcomes. Organizations across biotechnology, pharmaceuticals, diagnostics and healthcare are investing heavily in technologies that generate deeper biological insights, accelerate discovery and speed up new therapies to market.
Those investments will shape product development, research partnerships and competitive advantage for years to come. Understanding the technologies behind precision medicine is becoming a business imperative, not just a scientific one.
Advances in genomic sequencing, AI, digital health and increasingly sophisticated cell analysis are giving researchers a far more complete picture of human biology than was possible even a decade ago. Together, these technologies are moving precision medicine from an aspirational concept toward routine clinical practice.
An Inflection Point
For years, precision medicine was viewed as an ambitious vision for the future. Today, it is becoming a commercial reality because the technology, economics and healthcare ecosystem have finally aligned.
What was once prohibitively expensive is becoming commercially viable. Technologies behind precision medicine—from next-generation sequencing to advanced cell analysis—are becoming more powerful, scalable and cost-effective. Many innovations that were once limited to leading academic research centers are becoming increasingly accessible to hospitals, clinical laboratories and biotechnology companies. At the same time, digital health tools like telehealth have expanded access to specialized care, helping bring precision medicine closer to everyday clinical practice.
The market reflects that momentum. Grand View Research estimates the global precision medicine market was valued at $116.6 billion in 2025 and projects it will grow to $405.1 billion by 2033. As adoption accelerates, investment is flowing not only into new therapies but also into the technologies that make precision medicine possible.
Just as importantly, patient expectations have evolved. Consumers have grown accustomed to personalized experiences in nearly every aspect of their lives, and they increasingly expect the same level of personalization in healthcare.
Better Data, Better Outcomes
For decades, medicine often relied on treating patients with similar symptoms in similar ways. Yet diseases are rarely that straightforward. Two patients with the same diagnosis may respond very differently to the same treatment because the biology driving their disease is fundamentally different.
Precision medicine changes that approach by allowing clinicians and researchers to understand disease at the cellular and molecular level before making treatment decisions.
That shift depends on better biological data. Genomic sequencing reveals genetic changes, while advanced cell analysis technologies such as flow cytometry identify and characterize individual cells and cell populations based on their unique biological markers, enabling monitoring of cellular responses to disease, treatment or other stimuli. Together, these technologies give clinicians a more complete picture of disease, helping improve diagnosis, guide treatment decisions and monitor patient response over time.
In minimal residual disease (MRD) monitoring for leukemia, clinicians can detect extremely small numbers of remaining cancer cells after treatment. Rather than waiting for symptoms to return, physicians can determine whether therapy is working, whether disease is returning and whether treatment should change—replacing guesswork with evidence-based decisions.
As advanced diagnostic technologies become faster, more sensitive and more affordable, this level of personalized care is becoming practical across a much broader range of healthcare settings.
AI As An Accelerator
Artificial intelligence will not replace the technologies behind precision medicine; it will make them even more valuable.
Modern genomic sequencing and cell analysis generate enormous volumes of biological data. AI can help organizations extract insights from that information faster, identify patterns that may otherwise remain hidden and make more informed decisions throughout research and clinical workflows.
Consider lymphoma, which includes dozens of biologically distinct cancers. Successfully treating each subtype depends on understanding the unique biological characteristics driving that patient’s disease. Advanced analytical technologies generate much of that critical data, while AI helps researchers interpret it at scale, accelerating both discovery and clinical decision-making.
Why Business Leaders Should Care
Scientific breakthroughs create lasting value only when they can be delivered efficiently, consistently and at scale. That is why the technologies enabling precision medicine are becoming strategic investments across the life sciences ecosystem.
For pharmaceutical companies, richer biological data can accelerate drug discovery by helping researchers identify promising candidates sooner and make better-informed development decisions. For healthcare providers, the priority is delivering better patient outcomes while improving operational efficiency.
Innovation is making both goals more achievable. Advances in sequencing, automation, AI, software and cell analysis are reducing costs, simplifying workflows and making sophisticated testing more accessible. Individual technologies continue to improve as well. For example, newer spectral flow cytometry platforms can generate richer biological data with simpler workflows, better sensitivity, lower cost and fewer patient samples than earlier systems, helping laboratories improve diagnostic efficiency, accuracy and precision, thereby expanding access to more personalized care.
Precision medicine will continue to reshape how therapies are discovered, how healthcare organizations operate and how patients receive care. The organizations that succeed will recognize that precision medicine is no longer a future aspiration. As costs continue to fall and enabling technologies advance, personalized care is becoming both a clinical reality and a competitive advantage for organizations prepared to embrace it.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
